Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing

Myasthenia gravis (MG) is a prototypical B cell-mediated autoimmune disease affecting 20–50 people per 100,000. The majority of patients fall into two clinically distinguishable types based on whether they produce autoantibodies targeting the acetylcholine receptor (AChR-MG) or muscle specific kinase (MuSK-MG). The autoantibodies are pathogenic, but whether their generation is associated with broader defects in the B cell repertoire is unknown. To address this question, we performed deep sequencing of the BCR repertoire of AChR-MG, MuSK-MG, and healthy subjects to generate ∼518,000 unique VH and VL sequences from sorted naive and memory B cell populations. AChR-MG and MuSK-MG subjects displayed distinct gene segment usage biases in both VH and VL sequences within the naive and memory compartments. The memory compartment of AChR-MG was further characterized by reduced positive selection of somatic mutations in the VH CDR and altered VH CDR3 physicochemical properties. The VL repertoire of MuSK-MG was specifically characterized by reduced V-J segment distance in recombined sequences, suggesting diminished VL receptor editing during B cell development. Our results identify large-scale abnormalities in both the naive and memory B cell repertoires. Particular abnormalities were unique to either AChR-MG or MuSK-MG, indicating that the repertoires reflect the distinct properties of the subtypes. These repertoire abnormalities are consistent with previously observed defects in B cell tolerance checkpoints in MG, thereby offering additional insight regarding the impact of tolerance defects on peripheral autoimmune repertoires. These collective findings point toward a deformed B cell repertoire as a fundamental component of MG.

[1]  G. Cutter,et al.  Randomized trial of thymectomy in myasthenia gravis. , 2016, Journal of thoracic disease.

[2]  E. Santos,et al.  Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases , 2016, Muscle & nerve.

[3]  H. Atkins,et al.  Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. , 2016, JAMA neurology.

[4]  Jason A. Vander Heiden,et al.  Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis , 2016, Annals of clinical and translational neurology.

[5]  Cornelia L Dekker,et al.  Individual heritable differences result in unique cell lymphocyte receptor repertoires of naïve and antigen-experienced cells , 2016, Nature Communications.

[6]  E. Meffre,et al.  Rituximab does not reset defective early B cell tolerance checkpoints. , 2016, The Journal of clinical investigation.

[7]  Steven H. Kleinstein,et al.  Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data , 2015, Bioinform..

[8]  Steven H. Kleinstein,et al.  The mutation patterns in B-cell immunoglobulin receptors reflect the influence of selection acting at multiple time-scales , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[9]  A. Cope,et al.  Immunoglobulin kappa variable region gene selection during early human B cell development in health and systemic lupus erythematosus. , 2015, Molecular immunology.

[10]  Robert K. Colwell,et al.  Unveiling the species-rank abundance distribution by generalizing the Good-Turing sample coverage theory. , 2015, Ecology.

[11]  G. Yaari,et al.  Automated analysis of high-throughput B-cell sequencing data reveals a high frequency of novel immunoglobulin V gene segment alleles , 2015, Proceedings of the National Academy of Sciences.

[12]  M. Sirota,et al.  Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis , 2014, Science Translational Medicine.

[13]  Steven H. Kleinstein,et al.  B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes , 2014, Science Translational Medicine.

[14]  K. Kleopa,et al.  A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. , 2014, Journal of autoimmunity.

[15]  J. Maessen,et al.  Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor. , 2014, Journal of autoimmunity.

[16]  S. Berrih-Aknin Myasthenia Gravis: paradox versus paradigm in autoimmunity. , 2014, Journal of autoimmunity.

[17]  Mark M. Davis,et al.  Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. , 2014, Cell host & microbe.

[18]  E. Eichler,et al.  Sequencing of the human IG light chain loci from a hydatidiform mole BAC library reveals locus-specific signatures of genetic diversity , 2014, Genes and Immunity.

[19]  David A. Hafler,et al.  pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires , 2014, Bioinform..

[20]  M. van der Burg,et al.  Wiskott–Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans☆ , 2014, Journal of autoimmunity.

[21]  D. Koller,et al.  High-resolution antibody dynamics of vaccine-induced immune responses , 2014, Proceedings of the National Academy of Sciences.

[22]  Steven H. Kleinstein,et al.  Models of Somatic Hypermutation Targeting and Substitution Based on Synonymous Mutations from High-Throughput Immunoglobulin Sequencing Data , 2013, Front. Immunol..

[23]  R. Cummings,et al.  Molecular Basis of 9G4 B Cell Autoreactivity in Human Systemic Lupus Erythematosus , 2013, The Journal of Immunology.

[24]  A. Vincent,et al.  MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters , 2013, PloS one.

[25]  I. Illa,et al.  Myasthenia gravis and the neuromuscular junction , 2013, Current opinion in neurology.

[26]  A. Marx,et al.  The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. , 2013, Autoimmunity reviews.

[27]  J. Goldstein,et al.  Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  Scott D Boyd,et al.  Convergent antibody signatures in human dengue. , 2013, Cell host & microbe.

[29]  D. Hafler,et al.  Specific peripheral B cell tolerance defects in patients with multiple sclerosis. , 2013, The Journal of clinical investigation.

[30]  Jamie K. Scott,et al.  Complete haplotype sequence of the human immunoglobulin heavy-chain variable, diversity, and joining genes and characterization of allelic and copy-number variation. , 2013, American journal of human genetics.

[31]  F. Zimprich,et al.  Epidemiology of myasthenia gravis in Austria: rising prevalence in an ageing society , 2012, Wiener klinische Wochenschrift.

[32]  Steven H. Kleinstein,et al.  Quantifying selection in high-throughput Immunoglobulin sequencing data sets , 2012, Nucleic acids research.

[33]  A. Vincent,et al.  Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects , 2012, Experimental Neurology.

[34]  J. Verschuuren,et al.  Long-lasting treatment effect of rituximab in MuSK myasthenia , 2012, Neurology.

[35]  Stephen L. Hauser,et al.  Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation , 2011, Proceedings of the National Academy of Sciences.

[36]  David Kipling,et al.  The Relationship between CD27 Negative and Positive B Cell Populations in Human Peripheral Blood , 2011, Front. Immun..

[37]  G. Dranoff,et al.  Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. , 2011, Blood.

[38]  J. Goldstein,et al.  Response of patients with refractory myasthenia gravis to rituximab: a retrospective study , 2011, Therapeutic advances in neurological disorders.

[39]  Y. Yamanashi,et al.  Autoantibodies to low‐density lipoprotein receptor–related protein 4 in myasthenia gravis , 2011, Annals of neurology.

[40]  Michal Barak,et al.  Somatic hypermutation and antigen-driven selection of B cells are altered in autoimmune diseases. , 2010, Journal of autoimmunity.

[41]  Robert C. Edgar,et al.  Search and clustering orders of magnitude faster than BLAST , 2010, Bioinform..

[42]  David Kipling,et al.  High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. , 2010, Blood.

[43]  Jan Berka,et al.  Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire , 2009, Proceedings of the National Academy of Sciences.

[44]  J. Bennett,et al.  Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis , 2009, Journal of Neuroimmunology.

[45]  Hedda Wardemann,et al.  B-cell tolerance checkpoints in health and autoimmunity. , 2008, Current opinion in immunology.

[46]  J. Newsom-Davis,et al.  The myasthenia gravis thymus: A rare source of human autoantibody-secreting plasma cells for testing potential therapeutics , 2008, Journal of Neuroimmunology.

[47]  A. Vincent,et al.  IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis† , 2008, Brain : a journal of neurology.

[48]  F. Dekker,et al.  Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1 , 2008, Journal of Neuroimmunology.

[49]  V. Pascual,et al.  Defective B cell tolerance checkpoints in systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[50]  A. Marx,et al.  Fewer thymic changes in MuSK antibody‐positive than in MuSK antibody‐negative MG , 2005, Annals of neurology.

[51]  E. Meffre,et al.  Impaired early B cell tolerance in patients with rheumatoid arthritis , 2005, The Journal of experimental medicine.

[52]  R. Pelanda,et al.  Receptor editing is the main mechanism of B cell tolerance toward membrane antigens , 2004, Nature Immunology.

[53]  M. Nussenzweig,et al.  Surrogate Light Chain Expressing Human Peripheral B Cells Produce Self-reactive Antibodies , 2004, The Journal of experimental medicine.

[54]  M. Nussenzweig,et al.  Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.

[55]  L. Phillips The Epidemiology of Myasthenia Gravis , 2003, Neurologic clinics.

[56]  A. Vincent,et al.  Unravelling the pathogenesis of myasthenia gravis , 2002, Nature Reviews Immunology.

[57]  H. Shiono,et al.  Somatic Hypermutation and Selection of B Cells in Thymic Germinal Centers Responding to Acetylcholine Receptor in Myasthenia Gravis1 , 2001, The Journal of Immunology.

[58]  Marie-Paule Lefranc,et al.  Nomenclature of the Human Immunoglobulin Heavy (IGH) Genes , 2001, Experimental and Clinical Immunogenetics.

[59]  A. Vincent,et al.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.

[60]  J. Xu,et al.  Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. , 2000, Immunity.

[61]  A. Vincent,et al.  Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library. , 1997, International immunology.

[62]  D. Burton,et al.  Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. , 1997, Journal of immunology.

[63]  J. Bach,et al.  Evidence for an antigen-driven selection process in human autoantibodies against acetylcholine receptor. , 1995, Molecular immunology.

[64]  Y. Richard,et al.  Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. , 1990, Journal of immunology.

[65]  R. Hohlfeld,et al.  Effector mechanisms in myasthenia gravis: End‐plate function after passive transfer of IgG, Fab, and F(ab′)2 hybrid molecules , 1986, Muscle & nerve.

[66]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[67]  G. Scadding,et al.  Acetylcholine receptor antibody synthesis by thymic lymphocytes , 1981, Neurology.

[68]  A Ikai,et al.  Thermostability and aliphatic index of globular proteins. , 1980, Journal of biochemistry.

[69]  A. Engel,et al.  Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies , 1976, The Journal of experimental medicine.

[70]  R. Grantham Amino Acid Difference Formula to Help Explain Protein Evolution , 1974, Science.

[71]  M. Hill Diversity and Evenness: A Unifying Notation and Its Consequences , 1973 .

[72]  J. M. Zimmerman,et al.  The characterization of amino acid sequences in proteins by statistical methods. , 1968, Journal of theoretical biology.

[73]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[74]  V. Giudicelli,et al.  IMGT(®) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. , 2012, Methods in molecular biology.

[75]  S. Gammeltoft,et al.  Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. , 1987, Clinical and experimental immunology.

[76]  Dexter S. Moore,et al.  Amino acid and peptide net charges: A simple calculational procedure , 1985 .

[77]  A. Chao Nonparametric estimation of the number of classes in a population , 1984 .